JNJ

JOHNSON & JOHNSON

Healthcare | Giga Cap

$2.83

EPS Forecast

$23,959

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-10-23

JNJ Q3 2026: Strong Core Momentum Lifts 2026 Guidance as MedTech Bets Pay Off

Ticker: JNJ | EPS: GAAP 0.09 for Q3; Adjusted EPS 2.59. Revenue forecast and earnings trajectory are at the center of traders’ screens as Johnson & Johnson reports third-quarter results that mix durable growth with notable one-time charges. The market will watch how EPS consensus compares to the adjusted figure and how the revenue forecast for 2026 lines up with peers navigating a post-pandemic healthcare landscape.

Lead Take: a quarter of growth, a chorus of charges, and a higher bar for 2026

Johnson & Johnson (NYSE: JNJ) posted a Q3 that staffers of the company will describe as a solid demonstration of its diversified health-care engine. Reported sales rose 5.9% to about $25.4 billion, supported by an operational growth rate of 6.0% and an adjusted-operational growth pace of 6.1%. The headline GAAP earnings per share was modestly hit by a one-time charge—talc litigation-related adjustments alongside acquisitions and collaborations—but the EPS line that investors care about on a normalized basis remained buoyant at $2.59. All of this feeds into a raised revenue forecast and a higher EPS consensus trajectory for the year.

Quarter in numbers

  • Sales: $25.4 billion, up 5.9% reported.
  • Operational growth: 6.0% (6.1% on an adjusted basis).
  • EPS (GAAP): $0.09 for Q3.
  • Adjusted EPS: $2.59, reflecting the absence of certain one-off charges.
  • One-time charges: Provisions tied to talc litigation resolution, plus effects from the Firefly Bio acquisition and Sail Biomedicines collaboration.

Guidance and what it implies for 2026

The company is raising its full-year view, anchoring its narrative in a mid-point that implies roughly 7.4% growth at the top line for 2026. The revenue forecast now sits at about $101.2 billion at the midpoint. More importantly for investors, adjusted EPS guidance is lifted by $0.06 to $11.10 at the midpoint, signaling confidence in the underlying franchise even after accounting for the one-time items that distorted the GAAP path in the quarter.

Strategic highlights: OTTAVA, IMAAVY, and the pipeline push

Beyond the headline numbers, the quarter underscored a narrative shift: accelerated innovation and product-line expansion. Notably, the market authorizations and contemplated uses include:

  • OTTAVA, positioned as the world’s first table-integrated soft tissue robotic system, reflecting a bold move into advanced MedTech.
  • IMAAVY approval in warm autoimmune hemolytic anemia (wAIHA), signaling regulatory progress for niche therapies.
  • Priority review for RYBREVANT FASPRO in head and neck cancer, indicative of a continued push into oncology supportive care.
These moves sit alongside new partnerships and potential synergies from the Firefly Bio acquisition and the Sail Biomedicines collaboration, illustrating how JNJ balances core pharma strengths with a growing medical-device-orientated frontier.

From the top: management’s tone and what it portends

Joaquin Duato, JNJ’s Chairman and CEO, framed the quarter as a demonstration of momentum that could translate into durable, multi-year growth. The tone—optimistic but disciplined—suggests management sees scope to lift both topline and earnings as the year unfolds, even as tactical one-time items temper the GAAP picture. In markets where a handful of big bets can swing sentiment, the combination of robust organic growth and strategic M&A-style accelerants can push peers to recalibrate their own EPS consensus trajectories.

Implications for peers and the broader industry

JNJ’s Q3, with a raised revenue forecast and a higher EPS consensus path on an adjusted basis, can act as a table-stakes cue for fellow diversified-healthcare players: solid, sustainable growth supported by select innovations and careful handling of one-off charges. For medtech-focused peers, the OTTAVA narrative may accelerate R&D and capital allocation toward robotics-enabled care pathways. With talc-related headwinds still on the radar, sector peers will watch not just the numbers but how management communicates risk buffers and long-run strategy to investors.

Risks and caveats to weigh

The GAAP EPS was dented by a one-time charge tied to talc litigation and related arrangements. While adjusted metrics strip out such items, investors will continue to anchor judgments on whether the company can sustain the higher guidance in a mixed macro backdrop. Regulatory approvals, product-launch timelines, and integration of acquisitions remain key variables influencing the revenue forecast trajectory and the ultimate realization of the EPS consensus versus the reported numbers.

Conclusion: a pathway that blends resilience with reinvestment

Johnson & Johnson01’s Q3 2026 results sketch a company navigating through one-off headwinds while leaning into a growth trajectory built on heavy investments in medtech, oncology, and global consumer health initiatives. The raised 2026 guidance, anchored by a solid top-line outlook and a higher adjusted EPS target, suggests that the core franchise remains intact and that execution on strategic initiatives could yield incremental momentum for the sector peers as well. In equity markets, that translates into a narrative where the next steps matter as much as the current numbers—if you’re watching, you’ll want to see how the EPS and revenue forecast measures evolve quarter by quarter.

Note: The content above summarizes publicly disclosed material from Johnson & Johnson's Q3 2026 results press materials and Exhibit 99.1 filing. For investors, the key takeaways are the robust mid-year growth, one-time charges affecting GAAP metrics, the elevated 2026 revenue forecast, and the higher adjusted EPS guidance, alongside strategic product milestones shaping the company’s growth trajectory.